Joseph James Reilly net worth and biography

Joseph Reilly Biography and Net Worth

Insider of Ardelyx

Joseph Reilly is the Insider of Ardelyx. They are 52 years old.

What is Joseph James Reilly's net worth?: The estimated net worth of Joseph James Reilly is at least $939.58 thousand as of February 20th, 2026. Reilly owns 151,790 shares of Ardelyx stock worth more than $939,580 as of March 6th. This net worth approximation does not reflect any other investments that Reilly may own. Learn More about Joseph James Reilly's net worth.
How do I contact Joseph James Reilly?: The corporate mailing address for Reilly and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on Joseph James Reilly's contact information.
Has Joseph James Reilly been buying or selling shares of Ardelyx?: Within the last three months, Joseph James Reilly has sold $29,197.35 in Ardelyx stock. Most recently, Joseph James Reilly sold 4,991 shares of the business's stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85, for a transaction totalling $29,197.35. Following the completion of the sale, the insider now directly owns 151,790 shares of the company's stock, valued at $887,971.50. Learn More on Joseph James Reilly's trading history.
Who are Ardelyx's active insiders?: Ardelyx's insider roster includes John Bishop (Insider), Robert Blanks (Insider), James Brady (Insider), Eric Foster (Chief Commercial Officer), Elizabeth Grammer (Insider), Susan Hohenleitner (CFO), Jeffrey Jacobs (Insider), Mike Kelliher (Insider), David Mott (Director), Michael Raab (CEO), Joseph Reilly (Insider), Justin Renz (Chief Financial & Operations Officer), Susan Rodriguez (Insider), David Rosenbaum (Insider), Scott Sandell (Major Shareholder), and Laura Williams (Chief Medical Officer). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?: In the last year, Ardelyx insiders bought shares 5 times. They purchased a total of 1,214,710 shares worth more than $5,349,075.66. In the last year, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 575,834 shares worth more than $3,146,127.53. The most recent insider tranaction occured on February, 20th when Director David M Mott bought 333,333 shares worth more than $1,946,664.72. Insiders at Ardelyx own 4.8% of the company. Learn More about insider trades at Ardelyx.
Information on this page was last updated on 2/20/2026.

Joseph James Reilly Insider Trading History at Ardelyx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/20/2026	Sell	4,991	$5.85	$29,197.35	151,790

Joseph James Reilly Buying and Selling Activity at Ardelyx

Ardelyx Company Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $6.19

$6.04

$6.27

50 Day Range

MA: $6.87

$5.56

$7.99

2 Week Range

Now: $6.19

$3.21

$8.40

Volume

2,670,193 shs

Average Volume

4,212,689 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61